Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11601 - 11625 of 12789 in total
MTL-CEBPA is a SMARTICLES liposomal formulation of MTL-501, a small activating RNA (saRNA) oligonucleotide.
Investigational
Investigational
Investigational
Investigational
BRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of nasopharyngeal carcinoma.
Investigational
BNT111 is an investigational cancer immunotherapy under development for advanced melanoma. It consists of a fixed combination of mRNA-encoded, tumor-associated antigens.
Investigational
CT103A is an investigational BCMA-targeted genetically modified autologous T-cell immunotherapy.
Investigational
CT120 is an investigational autologous CD19/22 targeted CAR-T cell immunotherapy.
Investigational
ATI-1013 is a fully human nicotine-specific monoclonal antibody.
Investigational
BMN-351 is a fully modified 18-mer oligonucleotide with a TEG modification at its 5' end that binds to exon 51 of dystrophin pre-mRNA. It is under investigation for the treatment of Duchenne Muscular Dystrophy (DMD).
Investigational
VCN-01 is an investigational, genetically modified human adenovirus encoding human PH20.
Investigational
GX-G8 is a long-acting glucagon-like peptide 2 (GLP-2) being investigated for the treatment of short bowel syndrome.
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
XMT-2056 is a HER2-targeted antibody-drug conjugate (ADC) consisting of a HER2-targeted antibody conjugated with a stimulator of interferon genes (STING) agonist payload.
Investigational
Investigational
IBIO-100 is a high molecular weight multimer of E3-Fc, an endostatin C-terminus and IgG1-Fc fusion protein.
Investigational
Investigational
BD-111 is an HSV-1-erasing lentivirus-like particle delivering gRNA-expressing cassette and SpCas9 mRNA.
Investigational
Displaying drugs 11601 - 11625 of 12789 in total